In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A Wave of Success for Cambridge Heart

Executive Summary

For years, Cambridge Heart has been in an almost missionary mode. Since its founding in 1990, it has spent millions on R&D and sustained steady losses. But it finally looks like Cambridge Heart is well on the way to answering the two key questions for medical technology developers: clinical relevance and reimbursement. On March 21, the US Centers for Medicare & Medicaid Services issued a national coverage decision for Cambridge Heart's Microvolt T-Wave Alternans test for patients at risk of sudden cardiac death,

You may also be interested in...



Headlines Obscure Robust Year for Devices in 2006

Although big companies grabbed the headlines with problems, 2006 proved to be a strong year for the medical device industry and growth prospects look strong. Our selection of the device industry highlights of 2006 includes: Boston Scientific-Guidant deal: the winner may be Abbott; Device IPO market remains strong; Drug-eluting stent safety debate; Conflicts of interest: (physician relationships with companies); The bid for Biomet; VC Pendulum shifts towards medical devices; Kyphon bids for St. Francis; and Diagnostic imaging and in vitro diagnostics converge.

AHA Wrap-Up: Studies Emphasize Improved Outcomes, Cost Effectiveness

Cardiovascular investigators are now asking new questions, including how can treatment be targeted to those most likely to benefit, and when does aggressive treatment become too much? At the 2006 American Heart Association (AHA) meeting, these questions were at the top of everyone's list, and several highly anticipated studies attempted to provide some answers.

Risk Stratification for ICDs: The Debate Rages On

The clinical trials MADIT II and SCD-HeFT definitively proved the benefit of ICDs for preventing the risk of sudden cardiac death and paved the way for reimbursement. But now that the excitement has died down, the confusion has set in. Clinicians aren't entirely sure in which real-world patients to implant devices. The debate about the proper methods of risk stratifying patients for ICD implantation rages on.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV002740

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel